Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis

医学 类风湿性关节炎 内科学 甲氨蝶呤 羟基氯喹 人口 随机对照试验 关节炎 胃肠病学 外科 疾病 环境卫生 传染病(医学专业) 2019年冠状病毒病(COVID-19)
作者
Daniel H. Solomon,Jon T. Giles,Katherine P. Liao,Paul M Ridker,Pamela M. Rist,Robert J. Glynn,Rachel Broderick,Fengxin Lu,Meredith Murray,Kathleen M.M. Vanni,L Santacroce,Shady Abohashem,Philip M. Robson,Zahi A. Fayad,Venkatesh Mani,Ahmed Tawakol,Joan M. Bathon
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:82 (3): 324-330 被引量:28
标识
DOI:10.1136/ard-2022-223302
摘要

Objective Recent large-scale randomised trials demonstrate that immunomodulators reduce cardiovascular (CV) events among the general population. However, it is uncertain whether these effects apply to rheumatoid arthritis (RA) and if certain treatment strategies in RA reduce CV risk to a greater extent. Methods Patients with active RA despite use of methotrexate were randomly assigned to addition of a tumour necrosis factor (TNF) inhibitor (TNFi) or addition of sulfasalazine and hydroxychloroquine (triple therapy) for 24 weeks. Baseline and follow-up 18 F-fluorodeoxyglucose-positron emission tomography/CT scans were assessed for change in arterial inflammation, an index of CV risk, measured as an arterial target-to-background ratio (TBR) in the carotid arteries and aorta. Results 115 patients completed the protocol. The two treatment groups were well balanced with a median age of 58 years, 71% women, 57% seropositive and a baseline disease activity score in 28 joints of 4.8 (IQR 4.0, 5.6). Baseline TBR was similar across the two groups. Significant TBR reductions were observed in both groups—ΔTNFi: −0.24 (SD=0.51), Δtriple therapy: −0.19 (SD=0.51)—without difference between groups (difference in Δs: −0.02, 95% CI −0.19 to 0.15, p=0.79). While disease activity was significantly reduced across both treatment groups, there was no association with change in TBR (β=0.04, 95% CI −0.03 to 0.10). Conclusion We found that addition of either a TNFi or triple therapy resulted in clinically important improvements in vascular inflammation. However, the addition of a TNFi did not reduce arterial inflammation more than triple therapy. Trial registration number NCT02374021 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
称心青亦发布了新的文献求助10
刚刚
dgb发布了新的文献求助10
1秒前
hhh关注了科研通微信公众号
1秒前
小蛇玩发布了新的文献求助20
1秒前
赤壁发布了新的文献求助100
1秒前
2秒前
2秒前
2秒前
胡123456789发布了新的文献求助10
2秒前
盐烤香鱼发布了新的文献求助10
3秒前
瑾色完成签到,获得积分10
3秒前
3秒前
cc完成签到,获得积分10
3秒前
4秒前
chs110完成签到,获得积分20
4秒前
enough完成签到,获得积分10
4秒前
希望天下0贩的0的应助被lili采纳,获得10
4秒前
4秒前
zxy的应助被风趣的扬青采纳,获得10
4秒前
在水一方的应助被淳于易形采纳,获得10
4秒前
4秒前
秋风的应助被guanshujuan采纳,获得10
4秒前
刘婉敏发布了新的文献求助10
5秒前
没死就在完成签到,获得积分10
5秒前
5秒前
负责的绿柏完成签到,获得积分10
5秒前
独特忆南发布了新的文献求助10
5秒前
思源的应助被许可991127采纳,获得10
6秒前
bwf发布了新的文献求助10
6秒前
6秒前
李爱国的应助被dgb采纳,获得10
6秒前
6秒前
7秒前
一学僧完成签到,获得积分10
7秒前
wuyisha发布了新的文献求助10
7秒前
浮光发布了新的文献求助10
7秒前
怕孤独的考拉完成签到,获得积分10
8秒前
虚拟的如容完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178280
求助须知:如何正确求助?哪些是违规求助? 9569046
关于积分的说明 21802436
捐赠科研通 7773138
什么是DOI,文献DOI怎么找? 3432735
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478274